Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05145062 · ClinicalTrials.gov registry record
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
A clinical trial of Blood and Lymphatic Diseases, sponsored by Sangamo Therapeutics.
- Active
- Registry status
- 8
- Enrollment target
- 7
- Study locations
NCT05145062 is a study of Blood and Lymphatic Diseases that is active but no longer recruiting, run by Sangamo Therapeutics. The registered enrollment target is 8 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT05145062, a study of Blood and Lymphatic Diseases, is active but no longer recruiting, sponsored by Sangamo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 8 participants
- Enrollment target
- 7
- Study locations
Study Summary
Primary Objectives: Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST- 400 in participants with transfusion-dependent beta-thalassemia (TDT) Secondary Objectives: * Long-term efficacy of the biological treatment effect of BIVV003 in SCD * Long-term efficacy of the clinical treatment effect of BIVV003 on SCD-related clinical events * Long-term efficacy of the biological treatment effect of ST-400 in TDT * Long-term efficacy of the clinical treatment effect of ST-400 in TDT
Conditions Studied
Interventions
- DRUG BIVV003
- DRUG ST-400
Study Locations (7)
California
- UCSF Benioff Children's Hospital - Oakland
- University of California Davis Health System - Sacramento
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Health System - Detroit
Georgia
- Children's Healthcare of Atlanta - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2038-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05145062
The ClinicalTrials.gov registry entry for NCT05145062 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Blood and Lymphatic Diseases appearing as the primary indexed condition, and to 2 interventions - of which BIVV003 is the first listed.
NCT05145062 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Michigan, Georgia.
Frequently Asked Questions
What is clinical trial NCT05145062 about?
NCT05145062 is a clinical study titled "Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.". Primary Objectives: Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST- 400 in participants with transfusion-dependent beta-thalassemia (TDT) Secondary Objectives: * Long-term efficacy of the biological treatment effect of BIVV003 in SCD * Long-term efficacy ...
What is the current status of trial NCT05145062?
This trial is currently active not recruiting. The enrollment target is 8 participants. The study started on 2021-12-21. Estimated completion is 2038-07-14.
What conditions does trial NCT05145062 study?
This clinical trial studies the following conditions: Blood and Lymphatic Diseases.
What interventions are being tested in trial NCT05145062?
The interventions under investigation include: BIVV003 (DRUG), ST-400 (DRUG).
Who is sponsoring clinical trial NCT05145062?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05145062 being conducted?
This trial has 7 study locations across California, Georgia, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.